AUTHORS
Veronica Gonzalez-Calle, MD, PhD, Alexia Suarez Cabrera, MD2, Albert Oriol Sr, MD3, Borja Puertas, MD, PhD4, Esther González García5, Enrique Ocio Sr, MD, PhD6, Begoña Navarro-Almenzar, MD7, Beatriz Rey-Bua, MD8, Laura Rosiñol Dachs Sr, MD, PhD9, Sebastián Garzón10, Esperanza Lavilla11, Marta Sonia Gonzalez Perez, MD12, Joan Bargay, MD, PhD13, Noemi Puig, PhD14, Maria Teresa Cedena Romero, MD15, Bruno Paiva, PhD16, Juan-Jose Lahuerta Palacios, MD, PhD17, Joan Batista Blade Creixenti Sr, MD18, Jesus San-Miguel Sr, Md, PhD19, Maria-Victoria Mateos Jr, MD, PhD20
AFFILIATIONS
1 Servicio de Hematología, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain, Salamanca, Spain
2 Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain
3 Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
4 Servicio de Hematología, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain, Salamanca, Spain
5 Department of Hematology, Hospital Universitario de Cabueñes, Gijon, Spain
6 Servicio de Hematología y Hemoterapia, Hospital Universitario Marqués de Valdecilla University Hospital (IDIVAL) Universidad de Cantabria, Santander, Spain
7 Department of Hematology, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Pascual Parrilla, University of Murcia, Murcia, Spain
8 Servicio de Hematología, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain, Salamanca, Spain
9 Department of Hematology, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
10 Department of Hematology, University Hospital of Jerez, Jerez de la Frontera, Spain
11 Department of Hematology, Hospital Universitario Lucus Augusti, Lugo, Spain
12 Department of Hematology, IDIS, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
13 Department of Hematology, Hospital Universitari Son Llàtzer, Palma, Spain
14 Servicio de Hematología, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain, Salamanca, Spain
15 Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
16 Department of Hematology, Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Pamplona, Spain
17 Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain
18 Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain
19 Department of Hematology, Centre for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Pamplona, Spain
20 Servicio de Hematología, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain, Salamanca, Spain
ABSTRACT
Background: despite major advances in the treatment of triple-class exposed (TCE) relapse/ refractory multiple myeloma (RRMM), unmet clinical needs remain, especially for patients in early relapses. Elranatamab, a BCMAxCD3 biespecific antibody, has demostrated significant activity in TCE RRMM; however, data in earlier lines of therapy are limited. GEM-RANTAB is a phase II study designed to evaluate efficacy and safety of elranatamab in patients with early TCE RRMM in this setting. Here, we report the first results from the GEM-RANTAB study.
Methods: GEM-RANTAB is a multicenter, open-label, phase II trial enrolling patients with RRMM after 1 or 2 prior lines of therapy, previously exposed to an immunomodulatory drug (IMiDs), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (MoAb). Patients received elranatamab according to the approved dosing schedule but the duration of treatment is response-adapted and patients achieving minimal residual disease (MRD) negative by next generation flow (NGF) 10-5 and maintained for 12 months will stop therapy. The primary endpoint is the rate of MRD negativity by NGF with a sensitivity of at least 10-5 at 6 and 12 months. Secondary endpoints include overall response rate (ORR), and complete response rate (CR) according to the International Myeloma Working Group (IMWG) response criteria 2016, progression-free (PFS), overall survival (OS), or safety (Adverse events (AEs) graded per CTCAE v5.0). Here, we report the first results from the trial.
Results: 47 patients were enrolled. Median age was 74 years (range 50-81), 38.3% were female, ECOG performance status was 0 in 36.2% and 1 in 63.8%. High-risk cytogenetic abnormalities were present in 12.7%, ISS III stage in 35.6%. Overall, 10 (21.3%) patients had received 1 prior line of therapy and 37 (78.7%) had received 2 prior lines. All patients were TCE. Refractoriness to PI was present in 53.2%, to IMiDs in 74.4% (including 66.0% lenalidomide refractory), and to anti-CD38 MoAb in 80.8% of patients. Triple class refractoriness occurred in 40.4% of patients.
After a median follow-up of 8.2 months (range, 1-26), 38 patients were evaluable for the 6-month primary endpoint assessment. Four patients had discontinued treatment for reasons other than progression, and 5 patients had not yet reached cycle 6. Among evaluable patients, MRD negativity was achieved in 22/38 patients (57.8%) at 6 months. ORR was 71.1%, including 47.4% CR or better.
At the 12-month assessment, 23 patients had not yet reached this timepoint; including 19 who had not yet completed 12 treatment cycles. Among evaluable patients, MRD negativity was achieved in 14/24 (58.3%).
Overall, 12 (25.5%) had experienced disease progression, including 9 (21.4%) within the first 6 months, and 9 (21.4%) had died, primarily due to progressive disease. Median PFS was 16.9 months (95% IC, 11.2-NR) and median OS was 26.2 months (95% IC 15.2 - NR).
Regarding safety, cytokine release syndrome (CRS) occurred in 63.8% of patients, all grade 1-2, and were resolved. No ICANS events were observed. The most common non-CRS AEs were hematologic, including neutropenia (53.2%; grade ≥3, 38.3%) and only 4.3% of patients with febrile neutropenia), thrombocytopenia (23.4%; grade ≥3, 14.9%), and anemia (38.3%; grade ≥3, 12.8%). Despite protocol-recommended antimicrobial prophylaxis, infections were common, predominantly respiratory (57.4%; grade ≥3, 14.9%), followed by gastrointestinal (53.2%; grade ≥3,10.6%) and other infections (36.2%; grade ≥3, 14.9%). Cutaneous toxicity occurred in 38.3% (grade ≥3, 6.4%) and peripheral neuropathy in 19.1% (grade ≥3, 2.1%).
Conclusions: despite the ongoing maturation of the primary endpoint analysis, preliminary results demonstrate deep and durable responses with elranatamab in this poor prognosis earlier-line TCE RRMM population. The safety profile was consistent with previous reports of elranatamab, with no new safety signals and no severe CRS or any grade ICANS observed.
DISCLOSURES
Veronica Gonzalez-Calle, MD, PhD: No relevant conflicts of interest to declare.